» Authors » Anna Wesolowska

Anna Wesolowska

Explore the profile of Anna Wesolowska including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 127
Citations 922
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Partyka A, Golebiowska J, Marciniec K, Canale V, Trybala W, Satala G, et al.
Pharmacol Rep . 2025 Mar; PMID: 40064751
Background: Novel antipsychotics are characterized by multitarget profile of action, affecting among others, dopamine and serotonin receptors. In a series of experiments, we designed, synthesized and examined two new isoquinoline-sulfonamide...
2.
Jastrzebska-Wiesek M, Garbo S, Cios A, Wilczynska-Zawal N, Partyka A, Honkisz-Orzechowska E, et al.
ACS Chem Neurosci . 2025 Feb; PMID: 40020084
Among serotonin receptors, the 5-HT subtype is an important protein target and its ligands may play a key role in the innovative treatment of cognitive disorders. This study aimed to...
3.
Cios A, Chlon-Rzepa G, Jastrzebska-Wiesek M, Pociecha K, Wojcik-Pszczola K, Pekala E, et al.
Pharmacol Rep . 2024 Dec; 77(1):158-171. PMID: 39676141
Background: Research on new candidates for antidepressant/anxiolytic drugs from the long-chain arylpiperazines (LCAPs) group containing a 1,3-dimethylpurine-2,6-dione as a terminal amide fragment fits into the modern exploration trend. This study...
4.
Kucwaj-Brysz K, Bas S, Zeslawska E, Podlewska S, Jastrzebska-Wiesek M, Partyka A, et al.
ACS Chem Neurosci . 2024 Oct; 15(21):3884-3900. PMID: 39433990
Serotonin 5-HT receptor (5-HTR), one of the most recently discovered members of the serotonergic system, has become a promising target in the search for central nervous system disorders. Despite the...
5.
Pyka P, Haberek W, Wiecek M, Szymanska E, Ali W, Cios A, et al.
J Med Chem . 2024 Jan; 67(2):1580-1610. PMID: 38190615
Alzheimer's disease (AD) has a complex and not-fully-understood etiology. Recently, the serotonin receptor 5-HT emerged as a promising target for AD treatment; thus, here a new series of 5-HTR ligands...
6.
Sudol-Talaj S, Kucwaj-Brysz K, Podlewska S, Kurczab R, Satala G, Mordyl B, et al.
Eur J Med Chem . 2023 Sep; 260:115756. PMID: 37657272
Alzheimer's disease (AD), a neurodegenerative disorder with a complex aetiology, is the most common memory dysfunction particularly affecting the elderly. Various protein targets have been classified to be involved in...
7.
Czarnota-Lydka K, Sudol-Talaj S, Kucwaj-Brysz K, Kurczab R, Satala G, De Candia M, et al.
Eur J Med Chem . 2023 Aug; 259:115695. PMID: 37567058
Alzheimer's disease is becoming a growing problem increasing at a tremendous rate. Serotonin 5-HT receptors appear to be a particularly attractive target from a therapeutic perspective, due to their involvement...
8.
Partyka A, Gorecka K, Gdula-Argasinska J, Wilczynska-Zawal N, Jastrzebska-Wiesek M, Wesolowska A
Pharmaceuticals (Basel) . 2023 Jun; 16(2). PMID: 37259305
It is estimated that in patients taking antipsychotic drugs (APDs), metabolic syndrome occurs 2-3 times more often than in the general population. It manifests itself in abdominal obesity, elevated glucose...
9.
Lustyk K, Salaciak K, Jakubczyk M, Jastrzebska-Wiesek M, Partyka A, Wesolowska A, et al.
Neurochem Res . 2022 Nov; 48(3):839-845. PMID: 36350432
Anxiety is a common mental disorder, and its prevalence has lately increased because of the COVID-19 pandemic. Unfortunately, the available anxiolytics are often ineffective, and most possess addictive potential. Thus,...
10.
Jastrzebska-Wiesek M, Wesolowska A, Kolaczkowski M, Varney M, Newman-Tancredi A, Depoortere R
Behav Pharmacol . 2022 Jun; 33(5):333-341. PMID: 35695543
Tetrabenazine, a preferential inhibitor of the vesicular monoamine transporter type 2, depletes the brain monoamines dopamine, serotonin and norepinephrine. Tetrabenazine and deutetrabenazine (Austedo ®) are used to treat chorea associated...